Srujana Cherukuri, Ph.D.
Chief Executive Officer
Before becoming CEO, Dr. Cherukuri served in multiple roles at Noble Life Sciences including Chief Operations Officer, Chief Scientific Officer, Vice President of Product Development and Operations, and Director of Scientific Affairs. In her previous roles at Noble, Dr. Cherukuri was instrumental in optimizing new preclinical animal models and streamlining operations to achieve operational efficiency. In addition, Dr. Cherukuri led the successful consolidation of Noble operations at the Spring Valley Laboratories site. Prior to joining Noble, Dr. Cherukuri held positions at the Cleveland Clinic Foundation, National Cancer Institute and University of Maryland where she led projects focused on understanding the basic biology and mechanistic actions in cancer cells. Dr. Cherukuri has expertise in diverse areas of Biology and has 12+ years of research experience in the areas of oncology and stem cell biology. Dr. Cherukuri completed her PhD in biology at Cleveland State University.
Alain Cappeluti, CPA
Mr. Cappeluti has more than 30 years of experience in finance and public accounting for private and public companies, with more than 20 of those years spent in the biotech industry working for BioReliance, Human Genome Sciences (HGS), and CoGenesys. As the second employee of HGS in 1992 at the start of the human gene sequencing effort, he held positions of increasing responsibility and served for many years as Vice President of Finance. He has managed both large and small internal financial operations and has participated directly in approximately $4 billion of corporate financing transactions including private and public financings; IPOs; mergers and acquisitions; and real estate transactions. He led one of the largest real estate transactions in Maryland history while at HGS when the company executed a sale lease back on its corporate headquarters and large scale GMP manufacturing facilities. Mr. Cappeluti was part of the team that spun out Cogenesys from HGS in 2006 and was the CFO until the company was sold to Teva Pharmaceuticals in 2008. As a customer of CRO services in previous biotechnology industry positions, Mr. Cappeluti developed a keen awareness of quality and service issues that inform his leadership at Noble. He also serves on the board of O-Traces, Inc., an early stage cancer diagnostics company, and is a consultant to other life science companies.
Stephen K. Horrigan, Ph.D.
Chief Scientific Officer
Dr. Horrigan is an accomplished molecular geneticist who is known for his contributions to the development of innovative approaches for using genomic profiles and biomarkers to enhance drug discovery and development. Prior to joining Noble, Dr. Horrigan was the Vice President of Research at Avalon Pharmaceuticals a wholly-owned subsidiary of Clinical Data, Inc. During his tenure at Avalon, he held several positions of increasing responsibility within the research organization while directing both internal and collaborative research programs. He also played a key leadership role in the development of the company’s unique genomic biomarker-driven R&D platform. Dr. Horrigan has a strong expertise in the cellular control mechanisms of cancer and the use of biomarkers for the discovery and development of therapeutics and has multiple publications and patents in this area. Prior to joining Avalon, Dr. Horrigan was Associate Professor in the Department of Pediatrics and Lombardi Cancer Center at Georgetown University Medical Center where he led a research group focused on cancer genomics and the application of biomarkers in cancer diagnostics. He has also held positions at the University of Illinois, College of Medicine and the University of Chicago School of Medicine.
Jeffery W. Strovel, Ph.D.
Senior Vice President, Translational Research
Dr. Strovel has significant experience in developing and implementing innovative platforms for the discovery and development of biomarkers. For several years prior to the beginning of Noble, he was the Head of Discovery Research at Avalon Pharmaceuticals where he played a critical role in the development of many of the company’s novel biomarker-driven discovery systems while simultaneously leading discovery efforts including the company’s seminal product development candidate, a mechanistically novel cancer drug candidate targeting a major, previously intractable, target pathway in colorectal cancer. For this and other achievements, Dr. Strovel was recognized in four different years with the company’s “invention of the year” award. In addition, Dr. Strovel critically evaluated licensing opportunities, directed a team responsible for the discovery and validation of biomarkers in clinical specimens, and managed the biomarker assay group responsible for the development of pre-clinical and clinical biomarkers and the acquisition, processing, and interpretation of clinical biomarker data. Dr. Strovel has also led programs for small molecule drug discovery and development including drug target discovery, Hit to Lead, Drug lead optimization, in vitro and pharmacodynamic biomarker discovery. Earlier in his career, Dr. Strovel held positions at the University of Maryland and the National Cancer Institute.
Kenneth C. Carter. Ph.D.
Dr. Carter has been involved in the formation and early stage development of several biotechnology companies as a co-founder, consultant or member of the board of directors. He co-founded Avalon Pharmaceuticals, Inc. in January 1999 and served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. During this time, Avalon developed a unique biomarker-based drug discovery and development engine; completed an IPO and listing on the NASDAQ market; established drug discovery programs in colon, breast, pancreatic and hematological cancers; and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune. Prior to that, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. where he worked for several years and played a role in the discovery, cloning, and chromosomal mapping of dozens of novel human genes. Dr. Carter has served on the boards of directors for multiple biotechnology industry organizations including the Maryland Health Care Product Development Corporation and the National BIO Industry Organization. He also served recently as a special advisor to the Maryland Governor’s Life Sciences Advisory Board and is on the Advisory Council for the Center for Biotechnology Education at Johns Hopkins University where he also holds an adjunct faculty appointment.
Louis James DeTolla,V.M.D., M.S., PhD., DACLAM
Dr. DeTolla has more than 35 years of experience in laboratory animal and veterinary medicine. He serves as the Chief of Veterinary Resources for the University of Maryland, Baltimore. He is Director and Professor of Comparative Medicine and Professor in the Departments of Medicine (Infectious Diseases), Pathology, and Epidemiology, and Public Health in the University of Maryland, School of Medicine. He is also a member of the Marlene and Stewart Greenebaum Cancer Center. In addition, he is the Veterinary Medical Officer for the Baltimore Veterans Affairs Medical Center, Research Fellow with the National Aquarium, and Adjunct Research Scientist for the Mystic Aquarium Institute for Exploration. Dr. DeTolla has also served as Chief Attending Veterinarian for the Gerontology Research Center at the National Institute on Aging, Research Veterinarian and Co-Director of Laboratory Animal Research at Merck Sharp and Dohme Laboratories, Research Veterinarian at the Sloan-Kettering Institute for Cancer Research and Research Veterinarian at the Fox Chase Cancer Center, Institute for Cancer Research. Dr. DeTolla received an AB degree from Temple University, MS and PhD degrees from Rutgers University, and a VMD degree from the University Of Pennsylvania School Of Veterinary Medicine. He is a Diplomate of the American College of Laboratory Animal Medicine, a USDA-accredited veterinarian and licensed to practice in Maryland and Pennsylvania.